Biotech IP · Lead record
The independent claims are two-step: detect and reduce, then restore. Both halves are required, which is a narrower boundary than the abstract implies.
Biotech IP
US20260203900A1 claims a method that feeds an intraoperative fluorescence image to a GAN generator and returns a synthetic white-light photograph of the tissue's predicted future state. Claim 1 is canceled; claim 2 is the first operative claim.
Biotech IP
US20260199086A1, published July 16, 2026, claims methods rather than a device: three independent claims that define success by where the expanded frame ends up in the aortic root. It is a pending application, not a granted patent.
Biotech IP
A Regeneron application published July 16, 2026 claims an antibody that binds GDF8 with a GLP-1 receptor agonist tethered to it as payload. Its abstract says something different — which is exactly why the claims, not the summary, define the filing.
Biotech IP
A university-assigned granted patent claims a neural interface device — an implantable pulse generator plus a microelectrode catheter — placed into subarachnoid space or brain ventricles. What the independent claim actually covers.
Biotech IP
A granted patent claims an implanted accelerometer that infers device migration when it reads a non-standing posture while the patient is verifiably upright. A plain-terms walk through the independent claim.
Biotech IP
A granted patent claims accelerometer-based monitoring that watches a harvester mass charge an implant's battery and flags a failing harvester. Here is what the independent claim actually covers.
Biotech IP
A Biosense Webster application published July 2 claims a planar ablation end effector whose electrodes each span at least half the tip's length. The dependent claims add isolated diagnostic and contact electrodes, ceramic-dielectric materials, and a 600–1,200-volt drive range — all still pending examination.
Biotech IP
Independent claim 1 of a patent issued June 30 recites a two-diameter fixation mechanism that seats an electrode array inside a foramen of the sacrum. It is a granted patent, not a pending application, and it issued in a cluster of Medtronic device grants.
Biotech IP
A diagnostic-device application published this week recites a graphene field-effect transistor array, each sensor carrying a nucleic-acid probe on a graphene monolayer, for label-free multiplex readout. Two independent claims split the scope by how the probe is attached to the graphene, and the filing lands in the G01N 27/4145 FET-sensor neighborhood.
Biotech IP
In Enanta v. Pfizer, the Federal Circuit held the '048 provisional's disclosure of a C2-C12 alkyl substituent did not provide written description support for the '953 patent's C1 species, so the patent lost its priority date and was anticipated by Pfizer's intervening nirmatrelvir disclosure.
Biotech IP
A patent issued June 23, 2026 to Canon claims a flat-panel radiation detector that re-attributes each element's output to the spot where the X-ray first arrived, using angle-derived weights. The granted independent claim is directed to that output-correction scheme, and it lands in the A61B 6/03 computed-tomography imaging neighborhood.
Biotech IP
C12N is the Cooperative Patent Classification subclass that covers microorganisms, enzymes, and genetic engineering. It is the code you scan to map the gene-editing and biologics patent landscape.
Biotech IP
Biologics have their own patent-litigation choreography, separate from Hatch-Waxman. The BPCIA defines what a biosimilar is and lays out a staged information exchange — the so-called patent dance — under 42 U.S.C. 262.
Biotech IP
The long-running fight over foundational CRISPR-Cas9 patents is a priority dispute between UC Berkeley's group and the Broad Institute. In May 2025 the Federal Circuit vacated the Board's conception ruling and sent it back.
Biotech IP
A Paragraph IV certification is a generic applicant's statement that a listed patent is invalid or will not be infringed. Filing it under 21 U.S.C. 355(j) is the act that can trigger litigation and the 30-month stay.
Biotech IP
A patent term extension restores part of the patent life lost while a drug or device awaited FDA approval. Section 156 sets the formula — and two hard caps: five years of extension, and fourteen years of remaining term.
Biotech IP
The Supreme Court's Myriad decision held that a naturally occurring DNA segment is a product of nature and not patent-eligible merely because it has been isolated. The same opinion held that synthetic cDNA is eligible.
Biotech IP
Patent eligibility for diagnostic methods is decided under 35 U.S.C. 101 and the Mayo/Alice framework in MPEP 2106. A claim that merely correlates a measured metabolite to a treatment decision recites a law of nature.
Biotech
The ClinicalTrials.gov record for NCT01621581 shows the NINDS dose-escalation study of AAV2-GDNF, delivered by convection-enhanced delivery into the putamen, is now listed as completed with 25 participants.
Biotech
ClinicalTrials.gov records show the NINDS Phase 1 study of scAAV9/JeT-GAN, delivered by spinal injection to children and adults with a rare degenerative nerve disease, reached completion with 14 participants enrolled.
Biotech IP
A surgical-robotics application published this week recites a force sensor at the instrument tip wired back through a shielded cable to a circuit board. The independent claim is directed to the cabling and shielding, not the sensor itself, and it lands in the A61B 34/90 surgical-manipulator neighborhood alongside five companion filings.
Biotech
AbCellera's 8-K discloses an option-and-license collaboration with Jazz Pharmaceuticals built on its T-cell engager platform. Here is what the structure actually obligates and who controls the IP.
Biotech
An NCI Phase 1 study transduces a patient's own T cells with TCRs that recognize neoepitopes from TP53 and RAS mutations, targeting some of the hardest-to-treat hematologic malignancies (NCT06904066).
